Loading...

ESSA PHARMA INC Investments/Divestments 8-K Filing

SS P

ESSA PHARMA INC

()

2023 8-K

Acquisition Announcement

Special Meeting Approved

Legal Complaint Filed

Amendment Agreement

Meeting Adjourned

Correction Announcement

Capital Distribution Announced

Merger of Equals

Business Combination

Merger of Equals

Business Combination Agreement

Financial Statements

Annual Meeting Results

Financial Results

Financial Results

License Termination

Severance Plan Update

Trial Termination

Study Data Update

Financial Results Announcement

Financial Results Announcement

Meeting Results

Financial Results Announcement

Financial Results Announcement

Open Market Sale Agreement

Phase 2 Study Initiation

Amendments to Articles of I...

Financial Results Announcement

Appointment of Director

Earnings Report

Clinical Trial Support Agre...

Meeting Results

Earnings Reports

External Links:

ESSA Pharma announced the initiation of the Phase 2 portion of its study for masofaniten in combination with enzalutamide.

AI Assistant

ESSA PHARMA INC

2023

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.